A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 296 participants.
Also called NCT02973321
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 296 participants
- Sponsor
- Registry
-
NCT02973321 -
2016-001328-77
-
- Other papers using this trial's data
- Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Germany, Hungary, Mexico, Russia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02973321. Randomized; quadruple masking; primary purpose treatment. Start 2016-12-02 (actual); primary completion 2017-12-27 (actual). Results posted on 2021-02-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- SAR425899
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Liraglutide
- Intervention (Drug)
- Metformin
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02973321- Content hash
47b8d929c3fc4355d1770cbd7fc4d95b12299962588b3ccec5ea0de88c1649ad